Business
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
-- Growing body of data on REZLIDHIA® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"text","content":"-- Growing body of data on REZLIDHIA® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients --\n-- New data on olutasidenib in patients with mIDH1 myelodysplastic syndromes/neoplasms (MDS) --\nSOUTH SAN FRANCISCO, Calif., Nov. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.\n\"We are encouraged by the collective data supporting the potential use of REZLIDHIA in various mIDH1 AML patient populations, including those that are relapsed or refractory to hematopoietic stem cell transplant, ivosidenib, or venetoclax. These data continue to indicate this treatment could meaningfully improve the lives of underserved patients living with mIDH1 R/R AML,\" said Raul Rodriguez, Rigel's president and CEO. \"We are also excited by the compelling data in patients with mIDH1 MDS and look forward to evaluating this potential opportunity further. On top of the olutasidenib data, we are delighted to share other updates and data across our development portfolio, demonstrating our presence in the hematology-oncology space.\"\nDetails of the poster presentations and publication at the ASH Annual Meeting are as follows:\nPoster Presentations\nAbstract #: 2888Title: Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or VenetoclaxPresenter: Jorge E. Cortes, M.D., Director, Georgia Cancer Center, Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer, and Phase 2 Trial InvestigatorSession Name: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster IIDate: Sunday, December 10, 2023Presentation Time: 6:00-8:00 PM PTLocation: San Diego Convention Center, Halls G-H\nThis poster reports post hoc analyses from the registrational Phase 1/2 trial of olutasidenib, a small molecule, oral, mutated-IDH1 (mIDH1) inhibitor approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML), alone or in combination with az...